delolimogene mupadenorepvec
AXP000007.2 · Oncolytic virus
- Platform
- adenovirus (Ad5/35 chimera)
- Originator
- Lokon Pharma
- Sponsor
- Lokon Pharma
Names
| Name | Type | Source |
|---|---|---|
| delolimogene mupadenorepvec | preferred name, INN | curator, ncit |
| LOAd703 | code | ncit |
| Oncolytic Adenovirus LOAd703 | synonym | ncit |
Virus
- Role
- Oncolytic
- Family
- Adenoviridae
- Virus
- human adenovirus 5 (NCBI Taxonomy 28285)
- Strain
- Ad5/35 chimera
- Replication
- conditionally replicating
- Modifications
- Ad5 genome with Ad35 fiber; Delta-24 E1A
- Transgenes
- CD40LG, TNFSF9
- Route
- intratumoral
- Source
- evidence
Cross-references
- NCI Thesaurus
- C148462
- Wikidata
- Q140775700
- FDA UNII
- 3ZQ57V6YWZ
Approvals
No regulatory approval recorded.
Clinical trials (4)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT04123470 | A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma | Completed | Phase 1/2 | 2020-01-28 | 2023-07-30 | 24 | Malignant Melanoma |
| NCT03555149 | A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC) | Terminated | Phase 1/2 | 2018-09-27 | 2022-09-26 | 96 | Colorectal Cancer |
| NCT03225989 | Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer | Completed | Phase 1/2 | 2018-03-01 | 2023-08-22 | 47 | Biliary Carcinoma; Colorectal Cancer; Ovarian Cancer; Pancreatic Adenocarcinoma |
| NCT02705196 | LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer | Completed | Phase 1/2 | 2016-11 | 2025-11-15 | 51 | Pancreatic Cancer |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41698954 | LOAd703-induced tumor microenvironment gene engineering in combination with atezolizumab in metastatic malignant melanoma: a phase I/II trial. | Nature communications | 2026 | cited by trial NCT04123470 |
| PMID 41888981 | Reprogramming myeloid cells and restoring T cell fitness in checkpoint inhibitor resistant melanoma patients. | Biomarker research | 2026 | cited by trial NCT04123470 |
| PMID 42053989 | Tumor Microenvironment Gene Engineering with LOAd703 in Patients with Solid Malignancies: LOKON002 Phase I/IIb Clinical Trial. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2026 | name in title: LOAd703 |
| PMID 38547893 | LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study. | The Lancet. Oncology | 2024 | cited by trial NCT02705196 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41808784 | Safety of intratumoral immunostimulatory LOAd703 gene therapy combined with chemotherapy in patients with advanced cancer. | Immuno-oncology technology | 2026 | name in title: LOAd703 |
| PMID 42951313 | Immunostimulatory gene therapy with chemotherapy remodels pancreatic tumors and induces immune signatures associated with prolonged survival. | Journal for immunotherapy of cancer | 2026 | name in abstract: LOAd703 |
| PMID 40337771 | LOAd703 and chemotherapy combination in pancreatic cancer: insights from the LOKON001 study. | Translational gastroenterology and hepatology | 2025 | name in title: LOAd703 |
| PMID 33666760 | Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy. | Cancer immunology, immunotherapy : CII | 2021 | name in abstract: delolimogene mupadenorepvec |
| PMID 32355275 | Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40. | Cancer gene therapy | 2020 | name in abstract: LOAd703 |
| PMID 28536305 | Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2017 | name in abstract: LOAd703 |
Notes
Transgenes are trimerized membrane-bound CD40L and 4-1BBL, per the NCIt synonym; HGNC symbols assigned by the curator. Transgenes moved from targets to virus.tsv (spec 0.2).
How to cite
delolimogene mupadenorepvec (AXP000007.2). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000007.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.